Aneley Getahun Strobel, Aalisha Sahukhan, Anaseini Ratu, Jimaima Kailawadoko, Isireli Koroituku, Shalini Singh, Samuel McEwen, Sakiusa Baleivanualala, Mathilda Wilmot, Silivia Matanitobua, Kerrie Stevens, Anaseini Vesikula, Talica Cabemaiwai, Raquel Cooper, Mere Taufa, Jokaveti Tadrau, Kristy Horan, Daniel Faktaufon, Benjamin P. Howden, Eric Rafai
{"title":"耐多药脑膜炎奈瑟菌引起的 C 型脑膜炎球菌病爆发,斐济","authors":"Aneley Getahun Strobel, Aalisha Sahukhan, Anaseini Ratu, Jimaima Kailawadoko, Isireli Koroituku, Shalini Singh, Samuel McEwen, Sakiusa Baleivanualala, Mathilda Wilmot, Silivia Matanitobua, Kerrie Stevens, Anaseini Vesikula, Talica Cabemaiwai, Raquel Cooper, Mere Taufa, Jokaveti Tadrau, Kristy Horan, Daniel Faktaufon, Benjamin P. Howden, Eric Rafai","doi":"10.3201/eid3101.240476","DOIUrl":null,"url":null,"abstract":"<p>We describe an outbreak of invasive meningococcal disease (IMD) caused by <em>Neisseria meningitidis</em> serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji. Molecular testing was conducted at the Microbiological Diagnostic Unit in Melbourne, Victoria, Australia. During January 2016–December 2018, a total of 96 confirmed or probable IMD cases were reported. Of case-patients, 61.5% (59/96) were male and 38.5% (37) female, 84.4% (81) were indigenous people of Fiji, and 70.8% (68) were children <15 years of age. Annual incidence increased from 1.8/100,000 population in 2016 to 5.2/100,000 population in 2018. Serogroup C multilocus serotype 4821 that is resistant to ciprofloxacin was prevalent (62.1%, 41/66). Public health measures, which included targeted mass vaccination with monovalent meningitis C vaccine, were effective in controlling the outbreak. We observed a rapid decline in meningitis C cases in subsequent years.</p>","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"81 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji\",\"authors\":\"Aneley Getahun Strobel, Aalisha Sahukhan, Anaseini Ratu, Jimaima Kailawadoko, Isireli Koroituku, Shalini Singh, Samuel McEwen, Sakiusa Baleivanualala, Mathilda Wilmot, Silivia Matanitobua, Kerrie Stevens, Anaseini Vesikula, Talica Cabemaiwai, Raquel Cooper, Mere Taufa, Jokaveti Tadrau, Kristy Horan, Daniel Faktaufon, Benjamin P. Howden, Eric Rafai\",\"doi\":\"10.3201/eid3101.240476\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We describe an outbreak of invasive meningococcal disease (IMD) caused by <em>Neisseria meningitidis</em> serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji. Molecular testing was conducted at the Microbiological Diagnostic Unit in Melbourne, Victoria, Australia. During January 2016–December 2018, a total of 96 confirmed or probable IMD cases were reported. Of case-patients, 61.5% (59/96) were male and 38.5% (37) female, 84.4% (81) were indigenous people of Fiji, and 70.8% (68) were children <15 years of age. Annual incidence increased from 1.8/100,000 population in 2016 to 5.2/100,000 population in 2018. Serogroup C multilocus serotype 4821 that is resistant to ciprofloxacin was prevalent (62.1%, 41/66). Public health measures, which included targeted mass vaccination with monovalent meningitis C vaccine, were effective in controlling the outbreak. We observed a rapid decline in meningitis C cases in subsequent years.</p>\",\"PeriodicalId\":11595,\"journal\":{\"name\":\"Emerging Infectious Diseases\",\"volume\":\"81 1\",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2024-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Emerging Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3201/eid3101.240476\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3101.240476","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji
We describe an outbreak of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji. Molecular testing was conducted at the Microbiological Diagnostic Unit in Melbourne, Victoria, Australia. During January 2016–December 2018, a total of 96 confirmed or probable IMD cases were reported. Of case-patients, 61.5% (59/96) were male and 38.5% (37) female, 84.4% (81) were indigenous people of Fiji, and 70.8% (68) were children <15 years of age. Annual incidence increased from 1.8/100,000 population in 2016 to 5.2/100,000 population in 2018. Serogroup C multilocus serotype 4821 that is resistant to ciprofloxacin was prevalent (62.1%, 41/66). Public health measures, which included targeted mass vaccination with monovalent meningitis C vaccine, were effective in controlling the outbreak. We observed a rapid decline in meningitis C cases in subsequent years.
期刊介绍:
Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination.
Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.